Login to Your Account

Renovis, Pfizer Enter VR1 Inhibitor Deal Worth $187M

By Karen Pihl-Carey

Wednesday, June 1, 2005
About three weeks after Phase III data showed Cerovive hit its primary endpoint, Renovis Inc. formed a preclinical research deal with Pfizer Inc. worth up to $187 million or more for products that inhibit the vanilloid receptor (VR1). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription